News & Perspective

Oct 25, 2001

Oct 25, 2001

Studies raise hopes for invention of drugs to block anthrax toxin

Oct 25 (CIDRAP News) – Two studies published online by Nature this week help explain how anthrax toxin works, possibly paving the way for the development of drugs that could block the toxin's action. One group of researchers explains how it identified the cell-surface receptor that enables anthrax toxin to invade host cells, while another group describes the precise molecular structure of a key component of the toxin.

Nov 30, 2001

Nov 30, 2001

Acambis wins new contract to supply 155 million doses of smallpox vaccine

Nov 29, 2001 (CIDRAP News) – The US Department of Health and Human Services (HHS) has awarded Acambis Inc. a $428 million contract to produce an additional 155 million doses of smallpox vaccine by the end of 2002, HHS Secretary Tommy G. Thompson announced Wednesday.

Dec 10, 2001

Dec 10, 2001

HHS announces new bioterrorism research initiatives

(CIDRAP News) – The US Department of Health and Human Services (HHS) has announced seven new research grant programs to speed efforts to prevent, diagnose, and treat diseases related to bioterrorism.

Dec 19, 2001

Dec 19, 2001

Anthrax vaccine to be offered to postal and Capitol workers

(CIDRAP News) – Because of a small theoretical risk that anthrax spores can hide in the lungs for up to 100 days and grow after antibiotic treatment is stopped, the anthrax vaccine and an extension of antibiotic treatment will be offered to people who may have been exposed in the recent anthrax attacks, federal health officials announced yesterday afternoon.

Mar 18, 2002

Mar 18, 2002

NIAID releases lengthy bioterrorism research agenda

(CIDRAP News) – The National Institute of Allergy and Infectious Diseases (NIAID) has released a 68-page report on its plan for expanding research on "Category A" bioterrorism agents: anthrax, smallpox, plague, tularemia, viral hemorrhagic fevers, and botulism.

Mar 29, 2002

Mar 29, 2002

NIAID study: Diluted smallpox vaccine remains potent

A study indicates that the existing smallpox vaccine remains effective after being diluted five-fold and ten-fold, suggesting that the 15-million dose US stockpile can be stretched much further.

Jun 28, 2002

Jun 28, 2002

Trial of Aventis smallpox vaccine getting under way

(CIDRAP News) – A clinical trial of the decades-old supply of smallpox vaccine held by Aventis Pasteur is in progress, and early signs are that the vaccine is still potent, according to a spokesman for the National Institute of Allergy and Infectious Diseases (NIAID).

Nov 14, 2002

Nov 14, 2002

HHS to study whether chronic wasting disease threatens humans

Editor's note: This story was updated Nov 15 to include additional information from Food and Drug Administration officials.

(CIDRAP News) – Federal health officials have announced plans to expand research on whether chronic wasting disease (CWD) in deer and elk poses a threat to humans and other species.

Nov 26, 2002

Nov 26, 2002

Study to check smallpox immunity in people inoculated decades ago

(CIDRAP News) – About 900 adults who received smallpox shots in childhood are being revaccinated in a multicenter study to determine whether they still have any immunity to smallpox.

Dec 16, 2002

Dec 16, 2002

Half of second target group for smallpox shots may refuse them, officials estimate

(CIDRAP News) – Federal health officials project that about half of the estimated 10 million health and emergency response workers targeted for the second round of smallpox vaccinations will refuse the shots.

Pages

Sort Results

 

Narrow results

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»